Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. // Blood. – URL: https://www.sciencedirect.com/science/article/pii/S0006497126017659?dgcid=rss_sd_all
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004. Blood. https://www.sciencedirect.com/science/article/pii/S0006497126017659?dgcid=rss_sd_all
“Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.” Blood.
@article{article38053,
title = {Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004},
journal = {Blood},
url = {https://www.sciencedirect.com/science/article/pii/S0006497126017659?dgcid=rss_sd_all}
}